articleJournal of Clinical OncologyJan 3, 2008BRONZE OA

Short-Term Neoadjuvant Androgen Deprivation Therapy and External-Beam Radiotherapy for Locally Advanced Prostate Cancer: Long-Term Results of RTOG 8610

University of Rochester Medical Center · University of California, Los Angeles · +5 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Materials And Methods

Between 1987 and 1991, 456 assessable patients (median age, 70 years) were enrolled. Eligible patients had bulky (5 x 5 cm) tumors (T2-4) with or without pelvic lymph node involvement according to the 1988 American Joint Committee on Cancer TNM staging system. Patients received combined ADT that consisted of goserelin 3.6 mg every 4 weeks and flutamide 250 mg tid for 2 months before and concurrent with EBRT, or they received EBRT alone. Study end points included overall survival (OS), disease-specific mortality (DSM), distant metastasis (DM), disease-free survival (DFS), and biochemical failure (BF).

Results

Ten-year OS estimates (43% v 34%) and median survival times (8.7 v 7.3 years) favored ADT and EBRT, respectively; however, these differences did not reach statistical significance (P = .12). There was a statistically significant improvement in 10-year DSM (23% v 36%; P = .01), DM (35% v 47%; P = .006), DFS (11% v 3%; P

Citation impact

645
total citations
FWCI
46.20
Percentile
100%
References
33
Citations per year

Authors

10

Topics & keywords

Keywords
  • Medicine
  • Androgen deprivation therapy
  • Prostate cancer
  • Radiation therapy
  • External beam radiotherapy
  • Flutamide
  • Internal medicine
  • Oncology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding